Researchers at the Nagourney Cancer Institute are working with colleagues at the Federal University of Sao Paulo, the University of California, Irvine, and the Todd Cancer Institute in Brazil today. Gynecologic oncology Metabolic signs found in the blood of gynecologic cancer patients can identify patients at greatest risk of recurrence. This result could signal a future in which oncologists can better manage patients with advanced gynecologic malignancies using blood tests performed at the time of diagnosis.
Platinum resistance, defined as evidence of lack of response or clinical recurrence within 6 months of platinum-based chemotherapy, is an important determinant of gynecologic cancer survival.
“Using quantitative mass spectrometry, Metabolic signature Dr. Robert Nagourney, Founder and Director of Healthcare at the Nagourney Cancer Institute, said: Fast and efficient drug targeting. “
With growing interest in human metabolism as an important element of cancer biology, this study of gynecologic cancer breast cancer, Multiple myeloma and other cancers. This supports the role of metabolomics as one of the most promising platforms in cancer research.
In this study, 47 patients with ovarian or uterine adenocarcinoma who were candidates for carboplatin and paclitaxel were treated with isolated three-dimensional organoid metabolites and surgery used to measure platinum resistance in individual patients exvivo. Blood was submitted for specimen quantification. Results were correlated with response, time to progression, and survival.
NS study We identified patients with the highest risk of recurrence and death, with 92% sensitivity and 86% specificity.
“This insight has enabled us to more accurately determine the best course of treatment for patients with gynecologic tumors,” said Dr. Nagarney.
Paulo D’Amora et al, Platinum resistance in gynecologic malignancies: response, disease-free and overall survival predicted by biochemical characteristics: metabolomics analysis, Gynecologic oncology (2021). DOI: 10.1016 / j.ygyno.2021.08.001
Courtesy of Nagourney Cancer Institute
Quote: Platinum resistance in gynecologic malignancies: Responses predicted by biochemical features (October 26, 2021) and overall survival https: //medicalxpress.com/news/2021-10-platinum-resistance- Obtained from gynecologic-malignancies-response on October 26, 2021. html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
Reactions predicted by biochemical characteristics and overall survival
Source link Reactions predicted by biochemical characteristics and overall survival